Buscar resultados de ensayos clínicos
Peripheral Nervous System Neoplasms - 25 Studies Found
Estado | Estudiar |
Active, not recruiting |
Nombre del estudio: Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis Condición:
|
Active, not recruiting |
Nombre del estudio: Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) Condición: Neurofibromatoses Fecha: 2012-09-05 Intervenciones:
|
Completed |
Nombre del estudio: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condición: Neurofibromatosis Fecha: 2012-08-22 Intervenciones: Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects |
Withdrawn |
Nombre del estudio: Proton Radiation Therapy for Spinal Tumors Condición:
Fecha: 2012-03-13 Intervenciones:
|
Suspended |
Nombre del estudio: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Condición:
Fecha: 2011-07-25 Intervenciones: Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age > |
Completed |
Nombre del estudio: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condición:
Fecha: 2011-01-11 Intervenciones: Drug: Tasigna Following enrollment each subject will initially receive Tasigna orally at 200 mg twice da |
Active, not recruiting |
Nombre del estudio: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Condición:
Fecha: 2010-06-08 Intervenciones: Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Active, not recruiting |
Nombre del estudio: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Condición: Cutaneous Neurofibromas Fecha: 2009-06-15 Intervenciones: Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Active, not recruiting |
Nombre del estudio: Medical Treatment of "High-Risk" Neurofibromas Condición: Neurofibromatosis 1 Fecha: 2009-01-16 Intervenciones:
|
Terminated |
Nombre del estudio: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Condición: Neurofibroma Fecha: 2008-07-14 Intervenciones: Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |